About Us
About Us
Defining
Guided Hemostasis
Transradial access is expanding across interventional cardiology, radiology, neuroradiology, and structural heart. Every specialty that adopts it inherits the same unresolved problem: compression after each procedure is manual, unmeasured, and silently accumulates a permanent access risk that ~90% of the time goes undetected - until the patient returns for their next procedure and the radial is gone. Patent hemostasis reduces RAO incidence and, as demonstrated by Takamatsu et al. 2023, shortens hemostasis time by maintaining the flow balance that supports faster vascular repair.
IDAHealth is building Guided Hemostasis: the practice standard for real-time, objective, data-generating compression.
IdaFlo TR, powered by the IDASense platform, delivers continuous radial artery flow monitoring at the wrist.
Centers of Excellence across Amsterdam, Belgium, and the UK are building toward the standard today.
Our Mission
To make radial artery occlusion a preventable, not acceptable, outcome - and to build the clinical infrastructure that makes this standard achievable at scale across every specialty and program that depends on transradial access.
Our Vision
Guided Hemostasis as the universal standard wherever transradial access is used. Objective flow confirmation for every compression. Radial access preserved across a patient’s lifetime and across every specialty that needs it.
The Clinical Case for Guided Hemostasis
With the incidence of radial artery occlusion (RAO) as a prevalent complication post- transradial intervention, IdaHealth's solutions are more crucial than ever. Our approach is rooted in extensive research and a deep understanding of the clinical landscape, addressing pervasive unmet needs within the medical community.
Board of Directors
David L. Camp, Jr
With 25+ years of experience in medical device innovation, specializing in corporate operations, business development, sales, and marketing. Served as CEO of Orbus Medical Technologies (acquired by
OrbusNeich). Holder of numerous international and US patents.
Danny de Vries
Expert in steering the development of cutting-edge medical devices and systems, with a proven track record in managing complex R&D initiatives.
Rob de Ree
Rob de Ree served as CEO of Dezima Pharma (acquired by Amgen) and BMEYE (acquired by Edwards Lifesciences). He previously held leadership roles at Crucell, Medtronic, and Byk Gulden. Currently, he is a board member at Sirius Medical and an operating partner at Biogeneration Ventures. Rob holds a PharmD from the University of Groningen.
Kees Kolff
After a successful management buy out of a global business solutions company, ADM Group, Kees managed operations across EMEA and Asia before returning to Europe to take on the role of Executive Director. In this capacity, he focused on business development and M&A. Currently, he serves as an ambassador for ADM Group and as Chairman of the Board for one of its subsidiaries, ADM 360, a specialized solutions company within the hospitality industry.
Scientific Advisory Board
Dr. G. Amoroso, MD, PhD
Medical Director, OLVG Hospital
Key Opinion Leader in transradial
coronary procedures and miniaturization of interventional devices.
Prof. Stephane Carlier
University of Mons (UMONS)
Chief of Cardiology and Interventional Cardiologist at University Hospital Helora (Mons, Belgium) and Professor at UMons. An expert in complex coronary interventions, and AI in atrial fibrillation prediction, he also founded Coeur CoreLab and serves on advisory boards and journal review panels.
Dr. Jim Nolan
Leeds, United Kingdom
Professor James Nolan is a KOL in the field of optimized vascular access practice, with a strong track record of research, education, and training in trans-radial procedures
Daily Operations
David L. Camp, Jr
CEO and Co-Founder
Dr. G. Amoroso, MD, PhD
Medical Director
Lucien van Os
CTO
Kees Kolff
CCO
Marcel Haan
COO
